These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18157598)

  • 81. 3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world.
    Lin CC; Hsia TC; Chien CR
    Lung Cancer; 2012 Jun; 76(3):499-500. PubMed ID: 22503286
    [No Abstract]   [Full Text] [Related]  

  • 82. Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.
    Nishino M; Jackman DM; DiPiro PJ; Hatabu H; Jänne PA; Johnson BE
    Clin Radiol; 2014 Aug; 69(8):841-8. PubMed ID: 24857677
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Lung cancer: recent advances.
    Lee P
    Ann Acad Med Singap; 2010 Nov; 39(11):819-21. PubMed ID: 21165519
    [No Abstract]   [Full Text] [Related]  

  • 84. Selumetinib does not improve survival outcomes in NSCLC.
    Das M
    Lancet Oncol; 2017 Jun; 18(6):e313. PubMed ID: 28528747
    [No Abstract]   [Full Text] [Related]  

  • 85. Durvalumab boosts progression-free survival in NSCLC.
    Gourd E
    Lancet Oncol; 2018 Jan; 19(1):e11. PubMed ID: 29175147
    [No Abstract]   [Full Text] [Related]  

  • 86. Distinct evolutionary paths to TKI resistance in NSCLC.
    Niederst MJ; Engelman JA; Hata AN
    Cell Cycle; 2018; 17(3):298-299. PubMed ID: 27552405
    [No Abstract]   [Full Text] [Related]  

  • 87. Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer.
    Shi B; Zhang XB; Xu J; Huang XE
    Asian Pac J Cancer Prev; 2015; 16(13):5521-4. PubMed ID: 26225704
    [TBL] [Abstract][Full Text] [Related]  

  • 88. More haste, less speed.
    Lancet Oncol; 2003 Jun; 4(6):325. PubMed ID: 12788389
    [No Abstract]   [Full Text] [Related]  

  • 89. Randomized clinical trials with biomarkers: design issues.
    Freidlin B; McShane LM; Korn EL
    J Natl Cancer Inst; 2010 Feb; 102(3):152-60. PubMed ID: 20075367
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.
    Boehrer S; Adès L; Braun T; Galluzzi L; Grosjean J; Fabre C; Le Roux G; Gardin C; Martin A; de Botton S; Fenaux P; Kroemer G
    Blood; 2008 Feb; 111(4):2170-80. PubMed ID: 17925489
    [TBL] [Abstract][Full Text] [Related]  

  • 91. ["Targeted Therapies" in NSCLC - present and future].
    Pall G; Hilbe W
    Wien Med Wochenschr; 2007; 157(21-22):545-53. PubMed ID: 18157592
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Adjuvant TKIs in NSCLC: what can we learn from RADIANT?
    Hirsch FR; Bunn PA
    Nat Rev Clin Oncol; 2015 Dec; 12(12):689-90. PubMed ID: 26552954
    [No Abstract]   [Full Text] [Related]  

  • 93. Reply to N. Singh et al.
    Pérol M; Pérol D; Chouaid C
    J Clin Oncol; 2013 Mar; 31(9):1251-2. PubMed ID: 23616988
    [No Abstract]   [Full Text] [Related]  

  • 94. Darkening and eruptive nevi during treatment with erlotinib.
    Hemperly S; Ermolovich T; Lountzis NI; Sheikh HA; Purcell SM
    Cutis; 2019 Jul; 104(1):E19-E21. PubMed ID: 31487352
    [No Abstract]   [Full Text] [Related]  

  • 95. To target or not to target, that is the question.
    Garassino MC; Platania M; Broggini M; Torri V; De Braud F
    J Clin Oncol; 2013 Mar; 31(9):1254. PubMed ID: 23358979
    [No Abstract]   [Full Text] [Related]  

  • 96. Invited Commentary.
    Watzka SB
    Ann Thorac Surg; 2015 Aug; 100(2):421. PubMed ID: 26234831
    [No Abstract]   [Full Text] [Related]  

  • 97. Bilateral anterior uveitis secondary to erlotinib.
    Lim LT; Blum RA; Cheng CP; Hanifudin A
    Eur J Clin Pharmacol; 2010 Dec; 66(12):1277-8. PubMed ID: 20680254
    [No Abstract]   [Full Text] [Related]  

  • 98. Reply to M.C. Garassino et al.
    Ramalingam SS; O'Connell J; Liang JQ
    J Clin Oncol; 2013 Mar; 31(9):1255. PubMed ID: 23616990
    [No Abstract]   [Full Text] [Related]  

  • 99. ZD6474 headed for phase III trials in the fall.
    Oncology (Williston Park); 2005 Aug; 19(9):1140-2. PubMed ID: 16402511
    [No Abstract]   [Full Text] [Related]  

  • 100. Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study.
    Huang B; Tian L; Talukder E; Rothenberg M; Kim DH; Wei LJ
    JAMA Oncol; 2018 Jun; 4(6):874-876. PubMed ID: 29710201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.